NCT07803653
IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Notable Start date pushed from Oct 31, 2026 to Dec 31, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Patients undergo leukapheresis. Patients receive cyclophosphamide intravenously (IV) and fludarabine IV on days -5 to -3. Patients receive FH-STEAP1 IL-18 CAR T cell IV on day 0. Patients may continue to receive androgen deprivation therapy per standard of care, throughout the study. Patients undergo nuclear medicine bone scan, CT scan, MRI and/or PET scan, tumor biopsy and blood sample collection throughout the study. Patients may also undergo MUGA scan or echocardiography during screening.
Biologicals: FH-STEAP1 IL-18 CAR T cells
Drugs: Antiandrogen Therapy, Cyclophosphamide, Fludarabine
Procedures: Biospecimen Collection, Bone Scan, Computed Tomography, Echocardiography Test, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Biopsy Procedure
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States